PDF: A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis

PDF Download: Upadacitinib shows sustained long-term efficacy and safety for moderate-to-severe atopic dermatitis in 76-week studies. The oral JAK inhibitor maintains 80%+ EASI-75 response rates with manageable side effects, outperforming dupilumab in head-to-head trials while offering faster symptom relief for chronic eczema patients.
Read online:
A Review of the Long-Term Safety and Efficacy of Upadacitinib in the Treatment of Atopic Dermatitis